Physician profile
Laura B Summers
NPI 1992753503
$11,219.06
in general payments reported to CMS, 2019-2025
33 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,889 · 2020: $1,204 · 2021: $1,679 · 2022: $1,738 · 2023: $1,568 · 2024: $1,658 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,709.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,864.73 | 2019-2025 | |
| Amgen INC. | $1,243.22 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Pfizer INC. | $1,094.43 | 2019-2025 | |
| Janssen Biotech, INC. | $975.11 | 2019-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $926.61 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $833.04 | 2019-2023 | Krystexxa |
| Abbvie INC. | $705.49 | 2019-2025 | Rinvoq, Humira, Ubrelvy |
| Ucb, INC. | $590.59 | 2019-2024 | Cimzia, Bimzelx |
| Genzyme Corporation | $456.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $453.34 | 2019-2025 | Orencia |
| Lilly USA, LLC | $299.88 | 2019-2024 | Taltz |
| Genentech USA, INC. | $285.58 | 2019-2025 | Actemra |
| Astrazeneca Pharmaceuticals LP | $223.20 | 2021-2024 | Saphnelo |
| Sobi, INC | $157.47 | 2020-2023 | |
| Aurinia Pharma U.S., INC. | $149.86 | 2021-2024 | Lupkynis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.28 | 2019-2024 | Ofev, Cyltezo |
| Janssen Pharmaceuticals, INC | $142.27 | 2019 | |
| Radius Health, INC. | $130.38 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $77.01 | 2022-2024 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $72.09 | 2019-2022 | |
| Organon LLC | $45.50 | 2022-2024 | |
| Fresenius Kabi USA, LLC | $45.20 | 2023 | Idacio |
| Bioventus LLC | $44.18 | 2024 | Durolane |
| Access Pro Medical, LLC | $43.62 | 2025 | Matriderm |
| Celgene Corporation | $43.50 | 2019 | |
| Sandoz INC. | $32.59 | 2024 | Hyrimoz |
| Tersera Therapeutics LLC | $32.38 | 2019 | |
| Medexus Pharma, INC. | $23.45 | 2019 | |
| Zimmer Biomet Holdings, INC. | $18.67 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.66 | 2023 | Cuvitru |
| Shire North American Group INC | $16.01 | 2019 | |
| Antares Pharma, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Summers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.